*CHUN-I LIU1, Yuan-Jen Tsai2, Kah Kheng Goh3,4 (1. Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan, 2. Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan, 3. Department of Psychiatry, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan, 4. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan)
セッション情報
[CINP2024] Poster Session
CINP2024 » Poster Session
Schizophrenia 5 - Clinical (3)
2024年5月26日(日) 13:30 〜 14:30 CINP Poster Session Hall (Lobby Gallery)
*KuoHeng Cheng1, WenYu Hsu1 (1. Changhua Christian Hospital)
[P499] A Naturalistic Retrospective Study of Aripiprazole Once-Monthly 400 mg Used for Schizophrenia
*Nan-Ying Chiu1, Pei-Shan Kung1 (1. Lukang Christian Hospital)
*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Rodolfo Giuliani2, Richard Hartman3 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)
*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Richard Hartman3 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)
*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Francesca Sansi2, Rodolfo Giuliani2 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA)
*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Rodolfo Giuliani2, Richard Hartman3 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)
*Nobuhisa Kanahara1,13, Kazuki Okada2, Yuji Otsuka3, Remiko Kobayashi2, Hiroshi Kimura4, Hiroshi Yamanaka5, Yuri Takaoki6, Taisuke Yoshida7, Takahiro Oiwa8, Fumiaki Ito9, Hiroshi Komatsu10, Takashi Ono11, Yuki Kikuchi12, Takahisa Saiga6, Shingo Noda13, Masaomi Iyo2 (1. Chiba University Center for Forensic Mental Health, Chiba, Japan, 2. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan, 3. Department of Psychiatry, Asahi General Hospital, Asahi, Japan, 4. Department of Psychiatry, Gakuji-kai Kimura Hospital, Chiba, Japan, 5. Department of Psychiatry, Chiba Psychiatric Medical Center, Chiba, Japan, 6. Department of Psychiatry, Japanese Red Cross Narita Hospital, Narita, Japan, 7. Department of Psychiatry, Doujin-kai Kisarazu Hospital, Kisarazu, Japan, 8. Department of Psychiatry, Naoki-kai Isogaya Hospital, Ichihara, Japan, 9. Department of Psychiatry, National Hospital Organization Hanamaki Hospital, Hanamaki, Japan, 10. Department of Psychiatry, Tohoku University Hospital, Sendai, Japan, 11. Department of Psychiatry, Miyagi Psychiatric Center, Natori, Japan, 12. Department of Psychiatry, Yukou-kai, Kodama Hospital, Ishinomaki, Japan, 13. Department of Psychiatry, Ichihara-Tsuruoka Hospital, Ichihara, Japan)
*Ervana Ikha Yusnita1, Bintang Arroyantri Prananjaya2 (1. dr. H.M Rabain Muara Enim General Hospital, 2. Faculty of Medicine, Universitas Sriwijaya)
*Tianqi Gao1, Chengcheng Pu1, Haiyun Li2, Xin Yu1 (1. Peking University Sixth Hospital, Peking University Institute of Mental Health, 2. Medical Affairs, Sumitomo Pharma (Suzhou) Co., Ltd.)
*Mong-Liang Lu1,2,3, Kah Kheng Goh1,2, Tzu-Hua Wu3, Chun-Hsin Chen1,2 (1. Department of Psychiatry, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan, 2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 3. Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan)
*Yasushi Kawamata1,2, Norio Sugawara1,3, Taro Sasaki1,4, Saaya Yokoyama1,5, Hiroaki Okayasu1,6, Masataka Shinozaki1,7, Yoshitaka Takeuchi1,8, Aoi Sato1,9, Takaaki Ishikawa1,10, Hazuki Komahashi-Sasaki1,11, Kensuke Miyazaki12, Takashi Fukasawa13, Hanako Furukori14, Norio Yasui-Furukori1,3 (1. Department of Psychiatry, Dokkyo Medical University, School of Medicine, Tochigi, Japan, 2. Department of Psychiatry, Kikuchi Hospital, Tochigi, Japan, 3. Department of Psychiatry, TMC Shimotsuga, Tochigi, Japan, 4. Department of Psychiatry, Asahi Hospital, Tochigi, Japan, 5. Department of Psychiatry, Aoki Hospital, Tochigi, Japan, 6. Department of Psychiatry, Fudogaoka Hospital, Saitama, Japan, 7. Department of Psychiatry, Takizawa Hospital, Tochigi, Japan, 8. Department of Psychiatry, Okamotodai Hospital, Tochigi, Japan, 9. Department of Psychiatry, Muroi Hospital, Tochigi, Japan, 10. Department of Psychiatry, Saitama-Konan Hospital, Saitama, Japan, 11. Department of Psychiatry, Kanuma Hospital, Tochigi, Japan, 12. Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Aomori, Japan, 13. Department of Psychiatry, Seinan Hospital, Aomori, Japan, 14. Department of Neuropsychiatry, Kuroishi-Akebono Hospital, Aomori, Japan)
*Satoshi A Hayama1 (1. Faculty of Integrated Human Studies, Kyoto University, Kyoto, Japan)
*Ryo Asada1, Hikaru Hori1, Leo Gotoh1, Kiyohiro Yasumatsu1, Hitoshi Iida1, Hiroaki Kawasaki1 (1. Fukuoka University)
*Scott Vuocolo1, William P Horan1, Amy Claxton 1, Steven D Targum2, Inder Kaul1, Sharon Sawchak 1, Andrew C Miller 1, Steven M Paul1, Stephen K Brannan 1 (1. Karuna Therapeutics, Boston, MA, USA , 2. Signant Health, Boston, MA, USA)
*Ryotaro Kubota1, Satoru Ikezawa1,2, Hideki Oi3, Mari S Oba3, Shoki Izumi3, Leona Adachi1, Mako Miwa1, Ryoko Tsuno1, Shunji Toya4, Yohei Nishizato4, Daisuke Haga5, Tatsuro Iwane6, Kazuyuki Nakagome1 (1. Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan, 2. Department of Psychiatry, International University of Health and Welfare Mita Hospital, Tokyo, Japan, 3. Clinical Research and Education Promotion Division, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. CNS Group, Medical Science, Sumitomo Pharma Co., Ltd., Tokyo, Japan, 5. One More Job Training Institution, Toyonaka, Osaka, Japan, 6. Kyoto Prefectural Rakunan Hospital, Kyoto, Japan)
*Ho Chan Kim1, Seong Hwan Kim2 (1. Department of Psychiatry, Kosin University Gospel Hospital, Busan, Republic of Korea, 2. Department of Psychiatry, Dong-A University Hospital, Busan, Republic of Korea)
*Yasaman Kambari1,2, Jianmeng Song1,2, Aron Amaev1,2, Ali Abdolizadeh1,2, Edgardo Torres-Carmona1,2, Fumihiko Ueno1,2, Teruki Koizumi1,2, John Rutka3, Emma LeBlanc3, Neil Bailie3, Wanda Dillon3, Kaitlin Harvey3, Laurel Palmer3, Ariel Graff-Guerrero1,2, Philip Gerretsen1,2 (1. Centre for Addiction and Mental Health (CAMH), Toronto, Ontario , 2. Institute of Medical Science, University of Toronto, Toronto, Ontario, 3. Toronto General Hospital, Toronto, Ontario)
*Akiko Harada1, Shilpa Madari2, Arvid Jungnik3, Kerstin Breithaupt-Groegler3, Kathrin Hohl3 (1. Nippon Boehringer Ingelheim Co., Ltd, Hyogo, Japan , 2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 3. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany)